Abstracts Archive - Page 83 of 1683 - ATC Abstracts

2022 American Transplant Congress
De Novo DSA in the Setting of Stable Allograft Function is a Benign Finding
R. J. Knight, E. A. Graviss, D. T. Nguyen, T. N. Eagar, S. G. Yi, H. Podder, M. Hobeika, R. McMillan, A. O. Gaber
Houston Methodist Hospital, Houston, TX
*Purpose: We sought to determine the long-term outcome of renal allografts that developed de novo DSA (dnDSA) in the setting of stable renal function.*Methods: A…
2022 American Transplant Congress
Recipient Treatment with Anti-CD122 mAb Prolongs Kidney Allograft Survival During Antibody-Mediated Rejection without Impacting NK Cell Activation within the Graft
D. Okada, S. Miyairi, N. Dvorina, K. S. Keslar, A. Valujskikh, W. Baldwin, R. Fairchild
Cleveland Clinic, Cleveland, OH
*Purpose: Dysregulated donor-specific antibody (DSA) responses are induced in B6.CCR5-/- mice transplanted with complete MHC mismatched kidney allografts and are required for rejection of the…
2022 American Transplant Congress
Treatment Modality and Outcomes of Antibody-Mediated Rejection in Pediatric Kidney Transplant Recipients: The PARAMOUr Study
R. Engen¹, A. Jain², N. Hayde³, A. Mansuri⁴, M. Kallash⁵, S. McEwen⁶, R. Garro⁷, C. Peterson⁸, R. Zahr⁹, L. Harshman¹⁰, D. Puliyanda¹¹, S. Solomon¹², K. Twombley¹³, I. Ashoor¹⁴
¹Pediatrics, University of Wisconsin Madison, Madison, WI, ²Wayne State University, Detroit, MI, ³Albert Einstein College of Medicine, New York, NY, ⁴Augusta University, Augusta, GA, ⁵The Ohio State University, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Emory University, Atlanta, GA, ⁸University of Utah Health, Salt Lake City, UT, ⁹The University of Tennessee Health Science Center, Memphis, TN, ¹⁰University of Iowa, Iowa City, IA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²New York Medical College, Valhalla, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴Louisiana State University, New Orleans, LA
*Purpose: Antibody-mediated rejection (AMR) is the leading cause of graft failure in kidney transplantation, but evidence for effective treatments is limited.*Methods: PARAMOUr is a retrospective…
2022 American Transplant Congress
Baseline Findings from the UREAACT Trial to Improve Medication Adherence in Youth with Kidney Transplants
S. Amaral¹, P. Kwong², J. Zhu², R. George³, N. Rodig⁴, B. Warady⁵, J. Smith⁶, A. Bobrowski⁷, D. Matossian⁸, N. Zelikovsky⁹, L. Schwartz¹, P. Reese², R. Goldfarb Terry¹, J. Reason², A. Chung¹, S. Furth¹
¹CHOP, Phila, PA, ²UPenn, Phila, PA, ³CHOA, Atlanta, GA, ⁴Boston Children's, Boston, MA, ⁵Children's Mercy, Kansas City, MO, ⁶Seattle Children's, Seattle, WA, ⁷Cleveland Clinic, Cleveland, OH, ⁸Lurie Children's, Chicago, IL, ⁹LaSalle Univ, Phila, PA
*Purpose: This abstract describes the design and baseline characteristics of participants in the U-REAACT trial, a study to improve medication adherence in youth with kidney…
2022 American Transplant Congress
Functional Recellularized Patient Derived Endothelium; A Human Vascular Graft Approach
H. Tejeda Mora¹, J. Willemse², Y. den Hartog¹, I. Schurink², M. M. Verstegen², J. de Jonge², R. C. Minnee², M. W. van den Hoogen², C. C. Baan¹, L. J. van der Laan², M. J. Hoogduijn¹
¹Transplant Institute - Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ²Transplant Institute - Department of Surgery, Erasmus Medical Center, Rotterdam, Netherlands
*Purpose: In transplantation, the endothelial lining is the first barrier between the donor organ and recipient immune system. Damaged endothelium exposes extracellular matrix (ECM) molecules…
2022 American Transplant Congress
Steatosis Following Liver Transplantation for Nonalcoholic Steatohepatitis is Associated with a Higher Rate of Cardiovascular Complications
W. Alhamoudi¹, S. Alqahtani², K. Bzeizi², A. Albenmousa², Y. Saleh², D. Broering², S. Alghamdi²
¹Medicine, King Saud University, Riyadh, Saudi Arabia, ²Liver Transplantation, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
*Purpose: Cirrhosis secondary to Nonalcoholic Steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) worldwide. Objectives: to evaluate the prevalence of…
2022 American Transplant Congress
Characteristics and Outcomes of Anhepatic Patients Listed for Liver Retransplantation
R. G. Kathawate¹, T. Ibeabuchi², P. Abt², T. Bittermann²
¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA
*Purpose: The frequency and outcomes of anhepatic patients listed for transplantation in the United States has not been previously described. The United Network for Organ…
2022 American Transplant Congress
Liver and Kidney Transplantation from Donation After Circulatory Death Heart Donors in the US: Better Early Outcomes with Normothermic Regional Perfusion versus Cold Flush
M. Rosenzweig¹, R. Ruiz², E. Martinez¹, A. Gupta¹, H. Fernandez¹, S. Lee¹, N. Onaca¹, J. Bayer¹, G. J. McKenna¹, T. Ma¹, G. Testa³, A. Wall¹
¹Baylor University Medical Center, Dallas, TX, ²Baylor University Medical Center, Fort Worth, TX, ³Baylor Dallas, Dallas, TX
*Purpose: Donation after circulatory death (DCD) heart donation is increasingly common in the US. The two methods for DCD heart donation are normothermic regional perfusion…
2022 American Transplant Congress
Immunogenicity of a 3rd Dose of Mrna Covid-19 Vaccine in Kidney Transplant Recipients Who Failed to Respond to 2 Prior Doses
W. Werbel¹, A. Karaba¹, T. Chiang¹, T. Liang¹, A. Massie¹, M. Bettinotti¹, W. Clarke¹, N. Watson², A. Tobian¹, C. Durand¹, N. Bridges², D. Rostrosen², C. Larsen³, P. Heeger⁴, D. Segev¹
¹Johns Hopkins, Baltimore, MD, ²NIAID, Bethesda, MD, ³Emory University, Atlanta, GA, ⁴Mt. Sinai School of Medicine, New York, NY
*Purpose: Kidney transplant recipients (KTRs) have diminished immune response and protection after 2-dose mRNA COVID-19 vaccination. It is unknown if additional doses improve neutralization of…
2022 American Transplant Congress
COVID-19 Infection Post-Transplant: What is the Collateral Damage to the Graft? A Case for Pre-Transplant Vaccination
A. Fabick¹, E. Overly¹, V. Rao², V. Rohan³, N. Patel¹, D. DuBay³, C. Candland³, N. Pilch¹
¹Department of Pharmacy, Medical University of South Carolina, Charleston, SC, ²Department of Transplant Nephrology, Medical University of South Carolina, Charleston, SC, ³Department of Transplant Surgery, Medical University of South Carolina, Charleston, SC
*Purpose: COVID-19 produces an unpredictable immune reaction and is challenging to manage during active infection and post-infection, in kidney transplant (KTX) recipients. The first peak…